Ubs Asset Management Americas Inc Amgen Inc Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Amgen Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 4,442,543 shares of AMGN stock, worth $1.17 Billion. This represents 0.38% of its overall portfolio holdings.

Number of Shares

4,442,543

Previous 4,178,147 6.33%

Holding current value

$1.17 Billion

Previous $1.31 Billion 9.65%

% of portfolio

0.38%

Previous 0.38%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$309.38 - $337.38 $81.8 Million - $89.2 Million	264,396 Added 6.33%	4,442,543 $1.43 Billion
Q2 2024 Aug 13, 2024	BUY	$262.75 - $319.31 $213 Million - $259 Million	811,613 Added 24.11%	4,178,147 $1.31 Billion
Q1 2024 May 15, 2024	SELL	$268.87 - $324.56 $68.5 Million - $82.6 Million	-254,619 Reduced 7.03%	3,366,534 $957 Million
Q4 2023 Feb 14, 2024	BUY	$255.7 - $288.46 $80.7 Million - $91 Million	315,503 Added 9.54%	3,621,153 $1.04 Billion
Q3 2023 Nov 13, 2023	SELL	$218.65 - $271.46 $606,753 - $753,301	-2,775 Reduced 0.08%	3,305,650 $888 Million
Q1 2023 May 15, 2023	BUY	$225.79 - $275.2 $747 Million - $910 Million	3,308,425 New	3,308,425 $800 Million
Q3 2022 Nov 14, 2022	SELL	$224.46 - $253.15 $28.7 Million - $32.3 Million	-127,693 Reduced 3.65%	3,369,304 $759 Million
Q2 2022 Aug 12, 2022	SELL	$230.71 - $256.74 $63.4 Million - $70.5 Million	-274,635 Reduced 7.28%	3,496,997 $851 Million
Q1 2022 May 16, 2022	BUY	$219.27 - $242.57 $36.7 Million - $40.6 Million	167,490 Added 4.65%	3,771,632 $912 Million
Q4 2021 Feb 14, 2022	BUY	$198.88 - $227.6 $24.7 Million - $28.3 Million	124,389 Added 3.57%	3,604,142 $811 Million
Q3 2021 Nov 15, 2021	BUY	$212.27 - $248.7 $6.6 Million - $7.73 Million	31,100 Added 0.9%	3,479,753 $740 Million
Q2 2021 Aug 16, 2021	BUY	$233.58 - $259.14 $9.24 Million - $10.3 Million	39,574 Added 1.16%	3,448,653 $841 Million
Q1 2021 May 14, 2021	SELL	$221.91 - $258.6 $2.13 Million - $2.48 Million	-9,580 Reduced 0.28%	3,409,079 $848 Million
Q4 2020 Mar 01, 2021	BUY	$216.38 - $257.67 $15.4 Million - $18.4 Million	71,386 Added 2.13%	3,418,659 $786 Million
Q3 2020 Nov 13, 2020	SELL	$234.65 - $260.95 $18 Million - $20.1 Million	-76,895 Reduced 2.25%	3,347,273 $851 Million
Q2 2020 Aug 14, 2020	BUY	$197.81 - $242.74 $79.8 Million - $97.9 Million	403,228 Added 13.35%	3,424,168 $808 Million
Q1 2020 May 15, 2020	BUY	$182.24 - $241.7 $23 Million - $30.5 Million	126,373 Added 4.37%	3,020,940 $612 Million
Q4 2019 Feb 14, 2020	BUY	$189.21 - $243.2 $9.31 Million - $12 Million	49,190 Added 1.73%	2,894,567 $698 Million
Q3 2019 Nov 14, 2019	SELL	$174.11 - $208.62 $21.9 Million - $26.2 Million	-125,705 Reduced 4.23%	2,845,377 $551 Million
Q2 2019 Aug 15, 2019	SELL	$166.7 - $195.41 $17.3 Million - $20.3 Million	-103,905 Reduced 3.38%	2,971,082 $0
Q1 2019 May 14, 2019	BUY	$180.87 - $203.88 $28.7 Million - $32.4 Million	158,737 Added 5.44%	3,074,987 $0
Q4 2018 Feb 13, 2019	BUY	$178.4 - $208.25 $45 Million - $52.5 Million	252,302 Added 9.47%	2,916,250 $568 Million
Q3 2018 Nov 14, 2018	SELL	$185.29 - $208.89 $21.1 Million - $23.8 Million	-114,054 Reduced 4.11%	2,663,948 $0
Q2 2018 Aug 14, 2018	SELL	$166.05 - $186.51 $901,817 - $1.01 Million	-5,431 Reduced 0.2%	2,778,002 $0
Q1 2018 May 14, 2018	SELL	$169.43 - $198.0 $7.4 Million - $8.65 Million	-43,676 Reduced 1.54%	2,783,433 $0
Q4 2017 Feb 09, 2018	BUY	$168.79 - $188.59 $2.15 Million - $2.4 Million	12,715 Added 0.45%	2,827,109 $0
Q3 2017 Nov 13, 2017	BUY	$167.29 - $191.0 $471 Million - $538 Million	2,814,394	2,814,394 $0

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Amgen Inc Transaction History